EDSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EDSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Edesa Biotech has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Edesa Biotech Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Edesa Biotech has no long-term debt (1). As of today, Edesa Biotech's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Edesa Biotech's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Edesa Biotech's Financial Strength distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Edesa Biotech's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-1.74 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Edesa Biotech's Interest Coverage for the quarter that ended in Dec. 2023 is
Edesa Biotech had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Edesa Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Edesa Biotech's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.078 | + | 0) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Edesa Biotech has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (NAS:EDSA) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Edesa Biotech has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of Edesa Biotech's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Lemieux | officer: Chief Financial Officer | 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6 |
Joan Chypyha | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Patrick Marshall | director | 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Van Der Velden Peter | director, 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Michael J Brooks | officer: President | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Pardeep Nijhawan | director, 10 percent owner, officer: Chief Executive Officer | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Jennifer M Chao | director | 7 PURITAN WOODS ROAD, RYE NY 10580 |
Frank R. Oakes | director, officer: President, CEO, & Director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
Sean Arthur Macdonald | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lorin K Johnson | director | 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303 |
Pardeep Nijhawan Medicine Professional Corp | 10 percent owner | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Paul William Pay | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Carlo Sistilli | director | C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6 |
Lumira Capital Investment Management Inc. | 10 percent owner | 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
Daniel E. Morse | director | C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 02-01-2023
By ACCESSWIRE ACCESSWIRE • 05-24-2022
By ACCESSWIRE ACCESSWIRE • 04-20-2023
By ACCESSWIRE • 10-27-2023
By ACCESSWIRE • 06-27-2023
By ACCESSWIRE ACCESSWIRE • 05-12-2023
By ACCESSWIRE • 11-21-2023
By ACCESSWIRE • 07-26-2023
By ACCESSWIRE ACCESSWIRE • 03-24-2023
By ACCESSWIRE • 09-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.